When was Alchemab founded?

Alchemab was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Alchemab located?

Alchemab is headquartered in London, United Kingdom.

Who is the current CEO of Alchemab?

Jane Osbourn of Alchemab. They have also founded 1 company.

Which legal entities is Alchemab associated with?

Alchemab is associated with ALCHEMAB THERAPEUTICS LTD.

How many employees does Alchemab have?

As of Sep 30, 2026, the latest employee count at Alchemab is 75.

Is Alchemab a funded company?

Alchemab is a funded company, having raised a total of $149M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2019.

How much is Alchemab worth?

The latest valuation of Alchemab is £***** as of Feb 22, 2023.

When was the latest funding round of Alchemab?

Alchemab's latest funding was a $***** Series A round on Jul 09, 2026, with participation from 1 investor.

What is the annual revenue of Alchemab?

Annual revenue of Alchemab is between £10M and £50M as on Dec 31, 2025

Where does Alchemab rank among its competitors?

Alchemab ranks 10th amongst 588 active competitors, of which 207 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Alchemab?

Alchemab's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Among them, Alchemab secured the most recent funding round in July, 2026.

Alchemab - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of antibody therapeutics for treating oncology and neurodegenerative conditions. This organization identifies drug targets by analyzing patient antibody repertoires through deep sequencing and computational analysis. The process focuses on identifying convergent protective antibody responses found in individuals who demonstrate resilience to specific diseases. These findings facilitate the creation of therapeutic candidates intended for clinical application.

Website: www.alchemab.com/
Social
Email ID: *****@alchemab.com

Key Metrics

Founded Year

2019

Location

London, United Kingdom

Stage

Series A

Total Funding

$149M in 6 rounds

Latest Funding Round

Series A, Jul 09, 2026, $*****

Post Money Valuation

£***** as on Feb 22, 2023

Investors

RA Capital Management & 15 more

Ranked

10^th among 588 active competitors

Annual Revenue

£10M - £50M as on Dec 31, 2025

Employee Count

75 as on Sep 30, 2026

Similar Companies

Denali Therapeutics & 633 more

View Alchemab's full profile

Alchemab is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ALCHEMAB THERAPEUTICS LTD CIN: 12156844 , United Kingdom, Active	Aug 13, 2019	£10M - £50M (As on Dec 31, 2025)	8 (As on Dec 31, 2020)

Alchemab has raised a total funding of $149M over 6 rounds. Its first funding round was on 2019. Its latest funding round was a Series A round on Jul 09, 2026 for $*****. 1 investor participated in its latest round. Alchemab has 12 institutional investors and 4 angel investors.

Here is the list of recent funding rounds of Alchemab:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 09, 2026	3522466	Series A	6578133	2257721	3680886	5175146
Sep 09, 2025	6231068	Series A	6093696	9768812	9453907	Ono Venture Investment & 5 more
Dec 16, 2022	7980019	Grant (prize money)	4968310	4815650	6958294	Innovate UK

Access funding benchmarks and valuations. Sign up today!

View details of Alchemab's funding rounds and investors

The founders of Alchemab are Ruth Mckernan, Jane Osbourn, Ben Larman, Rachael Bashford-Rogers and Uri Laserson. Jane Osbourn is the CEO of Alchemab.

Here are the details of Alchemab's key team members:

Ruth Mckernan: Co-Founder of Alchemab and founder of 1 other company.
Jane Osbourn: Co-Founder & CEO of Alchemab.
Contact Info: 1 email address
Ben Larman: Co-Founder of Alchemab.
Rachael Bashford-Rogers: Co-Founder of Alchemab.
Contact Info: 1 email address
Uri Laserson: Former Co-Founder of Alchemab.

Alchemab's Board of Directors

Alchemab's board has 5 active members. Catherine Elizabeth Bingham, Jane Katharine Osbourn, Andrew David Levin, Kevin Lee and John Hamer are independent board members.

Here is the list of Alchemab's board of directors:

Name	Type	Representing	Status	Duration
Catherine Elizabeth Bingham	Independent board member	-	Current	3y 2m
cdcehau	Independent board member	-	Current	1y 6m
mil{uuj	Independent board member	-	Current	6y 8m
usjaljc	Independent board member	-	Current	2y 9m
iqbuscn	Independent board member	-	Current	8y 8m

View details of Alchemab's Founder profiles and Board Members

Alchemab's employee count trend

Alchemab has 75 employees as of Sep 26. Here is Alchemab's employee count trend over the years:

Uncover Alchemab's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alchemab include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Here is the list of Top 10 competitors of Alchemab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
3rd	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Bain Capital & 17 others	67/100
4th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
5th	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Lilly & 20 others	66/100
6th	Akebia Therapeutics 2007, Cincinnati (United States), Public	Developing therapeutics solutions to treat patients with kidney disease	$91M	Genechem, Longitude Capital & 13 others	66/100
7th	Ardelyx 2007, Fremont (United States), Public	Developer of therapeutics for the gastrointestinal tract, cardio-renal, GI, and metabolic diseases	$61.1M	Amgen Business Development, New Enterprise Associates ... & 11 others	66/100
8th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
9th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, ATW Partners & 6 others	65/100
10th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, DHVC & 14 others	71/100